<DOC>
	<DOC>NCT00378482</DOC>
	<brief_summary>This study is intended to provide access to CP-675,206 for patients who have previously received CP-675,206 in a clinical trial.</brief_summary>
	<brief_title>A Rollover Study for Patients Who Received CP-675,206 in Other Protocols, to Allow the Patients Access to CP-675,206 Until This Agent Becomes Commercially Available or Development is Discontinued.</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Melanoma</mesh_term>
	<mesh_term>Carcinoma, Renal Cell</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Tremelimumab</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>The subject must have already received CP675,206 in another protocol Females of childbearing potential must agree to practice a form of effective contraception for 12 months following any dose of study drug. The definition of effective contraception will be based on the judgement of the investigator. Subject must be willing and able to provide written informed consent and to comply with scheduled visits and other trial procedures</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Melanoma and other tumors</keyword>
</DOC>